Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, B.
Right arrow Articles by Reynolds, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, B.
Right arrow Articles by Reynolds, C. P.
[Cancer Research 63, 1520-1526, April 1, 2003]
© 2003 American Association for Cancer Research


Experimental Therapeutics

Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine1

Bo Yang, Nino Keshelava, Clarke P. Anderson and C. Patrick Reynolds2

Division of Hematology-Oncology, Children’s Hospital Los Angeles and Departments of Pediatrics [C. P. A., C. P. R.] and Pathology [C. P. R.], University of Southern California, Keck School of Medicine, Los Angeles, California 90027

Relapse of neuroblastoma (NB) commonly occurs in hypoxic tissues. Buthionine sulfoximine (BSO), an inhibitor of glutathione (GSH) synthesis, is cytotoxic for NB cell lines in atmospheric oxygen (20% O2). Tirapazamine (TPZ) is a bioreductive agent that forms a toxic-free radical in hypoxia. We determined in four NB cell lines cytotoxicity using the DIMSCAN digital imaging fluorescence assay, glutathione (GSH) levels by the DTNB-GSSG reductase method, apoptosis, reactive oxygen species (ROS), and mitochondrial membrane potential ({Delta}{psi}m) by flow cytometry. Hypoxia (2% O2) antagonized BSO-mediated ROS, apoptosis, and cytotoxicity but not GSH depletion. TPZ synergistically enhanced BSO cytotoxicity in hypoxia for all four NB cell lines, achieving 2–4 logs of cell kill. BSO depleted GSH (8–42% of controls) in 20 and 2% O2, whereas TPZ only decreased GSH in hypoxia. Maximal GSH depletion was induced by BSO + TPZ. N-acetylcysteine abrogated GSH depletion caused by TPZ but not by BSO. BSO increased ROS, decreased {Delta}{psi}m, and caused apoptosis in 20% O2 (but not in 2% O2). TPZ elevated ROS in 2% O2 (but not in 20% O2), whereas BSO + TPZ increased ROS both in 20 and 2% O2. In hypoxia, TPZ alone or TPZ + BSO caused an 80% decrease of {Delta}{psi}m at 24 h, preceding apoptosis in 74–86% of cells at 48 h. Thus, hypoxia significantly antagonizes BSO-mediated cytotoxicity for NB cell lines, but TPZ reversed the inhibition of BSO-mediated cytotoxicity in hypoxia, causing increased ROS, {Delta}{psi}m decrease, GSH depletion, apoptosis, and synergistic cytotoxicity. These data additionally define the role of ROS in BSO-mediated cytotoxicity and suggest that combining BSO with TPZ could have clinical activity against NB in hypoxic sites.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
B. Yang and C. P. Reynolds
Tirapazamine Cytotoxicity for Neuroblastoma Is p53 Dependent
Clin. Cancer Res., April 1, 2005; 11(7): 2774 - 2780.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Cook, Z. Wang, S. Alber, K. Liu, S. C. Watkins, Y. Vodovotz, T. R. Billiar, and D. Blumberg
Nitric Oxide and Ionizing Radiation Synergistically Promote Apoptosis and Growth Inhibition of Cancer by Activating p53
Cancer Res., November 1, 2004; 64(21): 8015 - 8021.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Batra, C. P. Reynolds, and B. J. Maurer
Fenretinide Cytotoxicity for Ewing's Sarcoma and Primitive Neuroectodermal Tumor Cell Lines Is Decreased by Hypoxia and Synergistically Enhanced by Ceramide Modulators
Cancer Res., August 1, 2004; 64(15): 5415 - 5424.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Kaufman, O. Scharf, J. Arbeit, M. Ashcroft, J. M. Brown, R. K. Bruick, J. D. Chapman, S. M. Evans, A. J. Giaccia, A. L. Harris, et al.
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting
Cancer Res., May 1, 2004; 64(9): 3350 - 3356.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. L. Cowen, K. J. Williams, E. C. Chinje, M. Jaffar, F. C. D. Sheppard, B. A. Telfer, N. S. Wind, and I. J. Stratford
Hypoxia Targeted Gene Therapy to Increase the Efficacy of Tirapazamine as an Adjuvant to Radiotherapy: Reversing Tumor Radioresistance and Effecting Cure
Cancer Res., February 15, 2004; 64(4): 1396 - 1402.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Goto, B. Yang, D. Petersen, K. A. Pepper, P. A. Alfaro, D. B. Kohn, and C. P. Reynolds
Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines
Mol. Cancer Ther., September 1, 2003; 2(9): 911 - 917.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.